Alzheimer's disease

Alzheimer’s disease (AD) treatments are minimally effective, and the disease’s prevalence is expected to triple by 2050. Rigorous AD clinical trials are needed. That is what we do.

With years of experience in Alzheimer’s clinical trials and drug development in different phases, Julius Clinical has the skill to support investigator-initiated trials, observational studies, or to incorporate real-world data.

Meet our scientific leader for Alzheimer’s disease

Our leader in Alzheimer’s clinical studies is Dr. Jort Vijverberg, neurologist at the Brain Research Center and senior researcher at Alzheimercentrum Amsterdam, Amsterdam UMC. Jort is the principal investigator on numerous Alzheimer’s clinical trials and also serves as a consultant to the pharmaceutical industry.

Brain Clinical is Julius Clinical’s proprietary network for CNS clinical trials. This network includes highly experienced and devoted researchers who specialize in streamlined and rigorously executed clinical trials for Alzheimer’s disease treatments.

We’re proud partner of

We work closely with the Brain Research Center in the Netherlands, which specialises in high-quality clinical trial execution and scientific publication.

Read more

We also have a close partnership and short lines of communication with Amsterdam Neuroscience, with whom we integrate basic, translational, and clinical research into trials.

Read more

Julius Clinical has a proven track record of operational excellence developing innovative solutions in Alzheimer’s clinical studies. An example of one of our Alzheimer’s studies is the completed SAPHIR.

SAPHIR phase IIa


24 patients | 7 countries | 120 sites

Multicentre Project to assess the Safety and Tolerability of Treatment in Subjects with early stage Alzheimer’s Disease.

Phase III European

240 patients | 5 countries | 30 sites

Study to assess safety and efficacy in patients with mild cognitive impairment to mild dementia due to Alzheimer’s Disease.

Phase II Netherlands


13 patients | 1 country | 1 site

An EEG study to evaluate synaptic activity in subjects with mild to moderate Alzheimer’s Disease.

Phase II


200 patients | 7 countries | 36 sites

Multi-center study to evaluate the efficacy and safety in patients with mild cognitive impairment due to Alzheimer’s Disease or mild Alzheimer’s Disease.

Expert team

Planning and executing complex Alzheimer’s clinical studies requires specific scientific and operational expertise. Julius Clinical brings these together in a cohesive team that understands Alzheimer’s standards of care and the nuances of effectively running clinical trials in this area.

Lieza exalto

Related webinars

The Alzheimer’s disease drug development landscape

Hosted by: Julius Clinical. Speakers: Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMC Topics that are discussed during this webinar: All major trends in Alzh...

Speakers: Dr. Jort Vijverberg

Innovative Endpoints in Alzheimer’s Disease Clinical Trials

Together with our partner Brain Research Center, we presented the webinar:  Innovative Endpoints in Alzheimer’s Disease Clinical trials. During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the ...

Speakers: Dr. Jort Vijverberg

Alzheimer’s scientific insights

Explore our Alzheimer’s trial capabilities, case studies, and other resources.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn